FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for prediction of the outcome of squamous cell carcinoma of the tongue and oropharynx. Immunohistochemical determination of molecular markers is performed. A level of expression of molecular markers p16 and Ki-67 is determined. If p16 is more than or equal to 70 % of tumor cells and Ki-67 is more than 50 %, an increase in overall 3-year survival of the patients is predicted.
EFFECT: method provides predicting the outcome of squamous cell carcinoma of the tongue and oropharynx due to clinical information value with respect to biological behavior of the tumor and avoiding the effect on prediction of other metabolic causes.
1 cl, 1 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF EFFECTIVENESS OF CONSERVATIVE TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2023 |
|
RU2817324C1 |
| METHOD FOR PREDICTION OF DEVELOPING RECURRENCE AFTER COMBINED TREATMENT OF ORAL CANCER | 2023 |
|
RU2825290C1 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOMES OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS | 2009 |
|
RU2426991C2 |
| METHOD FOR PREDICTION OF DEVELOPMENT OF PROGRESSION IN A LONG PERIOD IN PATIENTS WITH SQUARE CELL CANCER OF THE HEAD AND NECK | 2021 |
|
RU2765013C1 |
| METHOD FOR TREATING OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2018 |
|
RU2689875C2 |
| METHOD FOR TREATMENT OF SQUAMOUS CELL P-16 POSITIVE OROPHARYNGEAL CANCER | 2020 |
|
RU2751818C2 |
| METHOD FOR DETECTING EFFICIENCY OF ANTI-TUMOR THERAPY OF SKIN MELANOMAS | 2004 |
|
RU2280483C2 |
| METHOD FOR REMISSION DURATION PREDICTION IN PATIENTS WITH VULVA CANCER | 2016 |
|
RU2624508C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTION OF METASTASES IN PATIENTS WITH STOMACH CANCER | 2010 |
|
RU2445632C1 |
